-
Regeneron’s Lynozyfic granted FDA accelerated approval to treat multiple myeloma
07 Jul 2025 11:58 GMT
… adults with relapsed or refractory multiple myeloma (MM).
Patients eligible for the …
-
Brightpath’s BP-2202 designated orphan drug for multiple myeloma
04 Jul 2025 16:16 GMT
… FDA for the treatment of multiple myeloma.
BioWorld Science Regulatory Cancer Immuno …
-
GPRC5D-Directed Therapies Market Is Anticipated To Gain Momentum During The Forecast Period (2025-2034) Owing To Unmet Need In Multiple Myeloma Delveinsight
03 Jul 2025 23:30 GMT
… patients diagnosed with multiple myeloma or smoldering multiple myeloma. Currently, TALVEY … DelveInsight
Related Reports
Multiple Myeloma Market
Multiple Myeloma Market Insights, Epidemiology … barriers, and key multiple myeloma companies, including Sanofi, …
-
Lynozyfic (linvoseltamab-gcpt) Granted FDA Accelerated Approval for Relapsed/Refractory Multiple Myeloma
03 Jul 2025 18:35 GMT
… represents meaningful progress for the multiple myeloma community. Lynozyfic demonstrated early, … new standard of care for multiple myeloma. Furthermore, given the strength … milestone. It provides appropriate multiple myeloma patients and their care teams …
-
Regeneron's Lynozyfic Gains Accelerated FDA Approval For Heavily Pre-Treated Multiple Myeloma
03 Jul 2025 13:41 GMT
… or refractory (R/R) multiple myeloma (MM) who have received at …
-
Regeneron Scores Multiple Myeloma Nod for Bispecific, Unlocking $600M Opportunity
03 Jul 2025 13:22 GMT
… patients with relapsed or refractory multiple myeloma. The pharma will market the … . Regeneron’s bispecific trails other multiple myeloma bispecifics, chief of which is … new standard of care for multiple myeloma.”
Lynozyfic, a bispecific antibody, works …
-
Regeneron nabs dosing edge with Lynozyfic’s FDA approval in multiple myeloma
03 Jul 2025 11:08 GMT
… BCMAxCD3 bispecific drug in the multiple myeloma (MM) treatment space.
Via … to provide significant benefit to multiple myeloma patients, society and the healthcare … Moran said: “[Lynozyfic] provides appropriate multiple myeloma patients and their care teams …
-
FDA accelerates linvoseltamab-gcpt approval for multiple myeloma
03 Jul 2025 04:04 GMT
… gcpt for certain patients with multiple myeloma.
Specifically, the approval … gcpt for relapsed or refractory multiple myeloma.
Linvoseltamab-gcpt (Lynozyfic, Regeneron … represents meaningful progress for the multiple myeloma community,” Sundar Jagannath, MD, …
-
FDA Approves Regeneron Multiple Myeloma Drug With Dosing Edge Over J&J and Pfizer Meds
03 Jul 2025 03:08 GMT
… bispecific antibody it developed for multiple myeloma, the second most common … Pfizer’s bispecific antibody for multiple myeloma is Elrexfio, which targets BCMA … — including other bispecific antibodies for multiple myeloma — carry similar black box warnings …
-
FDA Approves Linvoseltamab to Treat R/R Multiple Myeloma
03 Jul 2025 03:00 GMT
… treatment of relapsed or refractory multiple myeloma. Regeneron. News release. July … patients with relapsed or refractory multiple myeloma (LINKER-MM1). Clinicaltrials.gov. … treatment of relapsed/refractory multiple myeloma. Regeneron. News release. April …
About
© 1995-2025